An appeals court today tossed out a ban on Sanofi’s and Regeneron’s cholesterol drug Praluent and is giving the partners a second chance to prove they didn’t trample on Amgen patents in its development. The U.S. Court of Appeals today ruled that the judge in the trial over Praluent had made mistakes in what it […]